Iceland Seafood International hf: Annual General Meeting 26 March 2025 – “proposed resolutions”

Click here - to use the wp menu builder

News Room

Less than 1 min.Read

By Investing Today

March 11, 2025

The Annual General Meeting of Iceland Seafood International hf will be held on Thursday 26 March 2025 at 4pm at Hilton Reykjavík Nordica, Suðurlandsbraut 2, 108 Reykjavik, Iceland. The meeting will be in Icelandic.

Enclosed is the notice to convene the Annual General Meeting, proposed agenda and proposed resolutions for the Annual General Meeting.

Attachments

ISI_AGM_Board Proposals 2025
ISI_AGM_Notice to convene the AGM 2025

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Brookfield Wealth Solutions Subsidiary Receives Authorization in the United Kingdom

Viridien Announces the Successful Pricing of its $450 Million and €475 Million Senior Secured Notes Offering

Iceland Seafood International hf: Annual General Meeting 26 March 2025 – “proposed resolutions”

Condor Announces 2024 Year-End Results

Vortex Announces Proposed Share Consolidation

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Verde Announces Q4 and FY 2024 Results

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Topics

Condor Announces 2024 Year-End Results

Vortex Announces Proposed Share Consolidation

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Verde Announces Q4 and FY 2024 Results

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

GOGL – Filing of 2024 Annual Report on Form 20-F

Canacol Energy Ltd. Announces 2P Reserves and Deemed Volumes of 599 Bcfe Worth US$2.6B BTAX and 10 Year Reserve Life Index

Sulliden Mining Capital Announces Summer Exploration Plan for East Sullivan

Related Articles

Condor Announces 2024 Year-End Results

Vortex Announces Proposed Share Consolidation

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Verde Announces Q4 and FY 2024 Results

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Company

Headlines

Condor Announces 2024 Year-End Results

Vortex Announces Proposed Share Consolidation

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)

Verde Announces Q4 and FY 2024 Results

Newsletter